PITTSBURGH, April 1, 2024 /PRNewswire/ -- PANTHERx®Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by Edenbridge Pharmaceuticals for the distribution of Yargesa® (miglustat) capsules, the first oral treatment option for adults with mild to moderate Type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option.
Edenbridge Pharmaceuticals Names Douglas S. Boothe as CEO
Enforcement Report - Week of November 8, 2023
Edenbridge Pharma's Generic Doxepin Hydrochloride Receives Approval in the U.S.
PARSIPPANY, N.J.--(BUSINESS WIRE)--Edenbridge Pharmaceuticals, LLC (“Edenbridge”) today announced that DARTISLA ODT (glycopyrrolate) is now available by prescription in the United States through Phil, the commercialization partner and eHub for DARTISLA ODT, as well as in retail pharmacies throughout the country. To ensure access to patients in need, Edenbridge is sponsoring the DARTISLA ODT Copay Program, which allows eligible patients to obtain the product for as little as $0 when filled through Phil or $20 when filled at other pharmacies.
PARSIPPANY, N.J.--(BUSINESS WIRE)-- Edenbridge Pharmaceuticals,nLLC (“Edenbridge”) today announced that it has received approval from nthe U.S. Food and Drug Administration on its 505(b)(2) New Drug nApplication (NDA) for DARTISLA ODT (glycopyrrolate) orally ndisintegrating tablets. DARTISLA ODT is available in a 1.7 mg orally ndisintegrating tablet and is indicated for adults to reduce symptoms of anpeptic ulcer as an adjunct to treatment of peptic ulcer. Edenbridge nwill launch this product to the market in early 2022 as its first nbranded specialty prescription product.
PARSIPPANY, N.J.--(BUSINESS WIRE)--Edenbridge Pharmaceuticals, LLC (“Edenbridge”) today announced that it has received approval from the U.S. Food and Drug Administration on its 505(b)(2) New Drug Application (NDA) for DARTISLA ODT (glycopyrrolate) orally disintegrating tablets. DARTISLA ODT is available in a 1.7 mg orally disintegrating tablet and is indicated for adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer. Edenbridge will launch this product to the market in early 2022 as its first branded specialty prescription product.
Catalent, a global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics, cell and gene therapies and consumer health products, has signed a commercial supply agreement with Phathom Pharmaceuticals, a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, for its lead compound, vonoprazan, which is a novel, orally active-potassium competitive acid blocker (P-CAB).